SPECIAL NOTICE
Q -- Special Notice of Intent to Sole-Source: Procurement of Services to Conduct Proteomic Analysis of Radiation Induced Biomarkers in Human Serum
- Notice Date
- 8/21/2021 1:13:44 PM
- Notice Type
- Special Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Solicitation Number
- 75N91021Q00227
- Response Due
- 8/26/2021 2:00:00 PM
- Archive Date
- 09/10/2021
- Point of Contact
- Renee Jones-Chuang, Jolomi Omatete
- E-Mail Address
-
renee.jones-chuang@nih.gov, jolomi.omatete@nih.gov
(renee.jones-chuang@nih.gov, jolomi.omatete@nih.gov)
- Description
- OVERVIEW Notice ID: 75N91021Q00227 Contract Opportunity Type: Special Notice Product Service Code: Q301 � Medical � Laboratory Testing NAICS: 541990 � All Other Professional and Technical Services - $15.0 million BACKGROUND The National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Radiation Oncology Branch (ROB) studies glioblastoma (GBM) - the most common form of primary brain tumor found in adults in the United States.� The current standard of care for GBM includes surgical resection, a concurrent course of radiation therapy (RT) and temozolomide (TMZ) treatment, followed by adjuvant TMZ administration with a median survival of 14.6 months. However, even with this extremely poor prognosis, there is a small subset of patients that lives 5 years (10-15%).� Thus, NCI has undertaken attempts to develop screening tools with prognostic value for the identification of those patients with better outcomes.� Though no validated circulating biomarkers for GBM have been integrated into clinical practice, the use of circulating biomarkers for management of GBM remains an attractive approach due to accessibility, the ability to take serial samples, and low costs compared to alternative screening tools. Emerging circulating biomarkers for GBM have been identified in blood, urine and cerebrospinal fluid. Development of prognostic biomarkers in easily accessible serum samples have the potential to improve the outcomes of patients with GBM through personalized therapy planning. The ROB seeks to obtain scientific support services to conduct a large-scale proteomic biomarker screening for serum from clinical samples from patients with glioblastoma multiforme undergoing radiation therapy. The branch anticipates utilizing this data to identify novel radiation responsive proteins and to support further research to develop new clinical biomarkers with predictive, prognostic or diagnostic value. Details regarding the specifications for this acquisition can be found in Attachment 1 � Statement of Work. The response close date of this notice is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be awarded pursuant to the authority in FAR 13.106-1(b)(1) using simplified acquisition procedures. It is exempt from the requirements of FAR Part 6. This notice is not a request for competitive quotation; however, if any interested party � especially any small business � believes it can meet this requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. The NCI anticipates issuing a sole-source award to the following organization: SomaLogic 2945 Wilderness Place Boulder, CO 80301 This is a follow-on requirement for proteomic analysis. The study which this order will support is related to previous studies using the SOMAscan platform through the NIH NIAID Center for Human Immunology (CHI) core labs, and a previous purchase order issued by the NCI. These previous studies utilized the SOMAscan biomarker assay, so to ensure continuity of research and comparability of data, the NCI must use the same assay for this effort. The SOMAscan platform analyzes samples using novel, proprietary technology that is not available elsewhere on the market. Alternative analysis providers are incapable of scanning 7,000 analytes, which would severely limit the scope of this project. SomaLogic is thus the only vendor capable of providing these services, both due to the technical capability of their assay and the NCI�s need to compare results obtained from this analysis to results from previous efforts and studies. Responses must be received in the contracting office by the deadline stated in this notice. All responses and/or questions must be submitted via e-mail to Renee Jones-Chuang, Contract Specialist, at renee.jones-chuang@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification through SAM.gov and have representations and certifications completed. Responses should include both the STATEMENT OF CAPABILITY and the BUSINESS SIZE AND SOCIOECONOMIC STATUS information as explained below. This notice is to assist with determining sources only. If a solicitation is issued it will be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this announcement. REQUESTED INFORMATION (1) Statement of Capability: Submit a brief description (10-pages or fewer) that includes product specifications. Include past experience with performing this type of service for Government agencies, or for a private medical facility. Please indicate your address. (2) Business Size and Socio-Economic Status: (a) Indicate whether your organization is a small business or other-than-small business. (b) If small, indicate if your firm qualifies as a small, emerging business; or a small disadvantaged business. (c) If disadvantaged, specify under which disadvantaged group and if your firm is certified under Section 8(a) of the Small Business Act. (d) Indicate if your firm is a certified HUB-Zone firm. (e) Indicate if your firm is a woman-owned or operated business. (f) Indicate if your firm is a certified Service-Disabled Veteran Owned Small Business (SDVOSB) or a Veteran Owned Small Business (VOSB). (g) Include the DUNS number of your firm. (h) State whether your firm is registered in the System for Award Management (SAM).
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/8d8f4433403e4bf4a71f249dce07e1d4/view)
- Place of Performance
- Address: Rockville, MD 20852, USA
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN06106097-F 20210823/210821230109 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |